Broadening the therapeutic horizon of advanced biliary tract cancer through molecular characterisation
Biliary tract cancer (BTC) comprises a group of rare and anatomically distinct epithelial cell tumours of the biliary tree, including gallbladder carcinoma (GBC), intrahepatic cholangiocarcinoma (IHC) and extrahepatic cholangiocarcinoma (EHC), which together account for approximately 1% of adult cancers worldwide [1]. Despite being rare, BTCs are an important cause of cancer-related mortality and display a dismal prognosis, even with sequential chemotherapy. Geographically, the incidence of GBC is highest in Southeast Asia, Latin America and Eastern Europe and demonstrates a female preponderance [2,3].
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Avani Athauda, Caroline Fong, David K. Lau, Milind Javle, Ghassan K. Abou-Alfa, Chigusa Morizane, Keith Steward, Ian Chau Tags: Anti-tumour Treatment Source Type: research
More News: Bile Duct Cancer | Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Cholangiocarcinoma | Epithelial Cancer | Gallbladder Cancer